Systemic therapy for hepatocellular carcinoma

被引：72

作者：

Leung, TWT ^{[1
]}

Johnson, PJ ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 05期

关键词：

D O I：

10.1053/sonc.2001.26954

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：514 / 520

页数：7

共 63 条

[1]

ALIDRISSI H, 1982, HEPATO-GASTROENTEROL, V32, P8

[2] Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study [J].

BobbioPallavicini, E ;

Porta, C ;

Moroni, M ;

Bertulezzi, G ;

Civelli, L ;

Pugliese, P ;

Nastasi, G .

EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1784-1788

[3]

Browder T, 2000, CANCER RES, V60, P1878

[4] CONTROLLED TRIAL OF TAMOXIFEN IN PATIENTS WITH ADVANCED HEPATOCELLULAR-CARCINOMA [J].

CEREZO, FJM ;

TOMAS, A ;

DONOSO, L ;

ENRIQUEZ, J ;

GUARNER, C ;

BALANZO, J ;

NOGUERAS, AM ;

VILARDELL, F .

JOURNAL OF HEPATOLOGY, 1994, 20 (06) :702-706

[5] Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients [J].

Chao, Y ;

Chan, WK ;

Birkhofer, MJ ;

Hu, OYP ;

Wang, SS ;

Huang, YS ;

Liu, M ;

Whang-Peng, J ;

Chi, KH ;

Lui, WY ;

Lee, SD .

BRITISH JOURNAL OF CANCER, 1998, 78 (01) :34-39

[6] MDR1 (MULTIDRUG-RESISTANCE) GENE-EXPRESSION IN HUMAN PRIMARY LIVER-CANCER AND CIRRHOSIS [J].

CHENIVESSE, X ;

FRANCO, D ;

BRECHOT, C .

JOURNAL OF HEPATOLOGY, 1993, 18 (02) :168-172

[7]

CHLEBOWSKI RT, 1984, CANCER TREAT REP, V68, P487

[8]

Damrongsak C, 1973, J Med Assoc Thai, V56, P370

[9] MITOZANTRONE AS SINGLE AGENT THERAPY IN HEPATOCELLULAR-CARCINOMA - A PHASE-II STUDY [J].

DUNK, AA ;

SCOTT, SC ;

JOHNSON, PJ ;

MELIA, W ;

LOK, ASF ;

MURRAYLYON, I ;

WILLIAMS, R ;

THOMAS, HC .

JOURNAL OF HEPATOLOGY, 1985, 1 (04) :395-404

[10]

FALKSON G, 1984, CANCER, V54, P970, DOI 10.1002/1097-0142(19840915)54:6<970::AID-CNCR2820540604>3.0.CO

← 1 2 3 4 5 6 7 →